Barinthus Biotherapeutics plc

BRNS

US91864C1071

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
2.5 ^USD	+2.93%		-0.40%	-32.25%

Apr. 18	Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	MT
Apr. 18	BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections	CI

Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer

July 26, 2023 at 04:06 pm EDT

On July 20, 2023, Dr. Margaret Marshall notified Vaccitech plc of her intention to retire from her position as chief medical officer of the company, effective immediately.

Latest news about Barinthus Biotherapeutics plc

Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	Apr. 18	MT
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections	Apr. 18	CI
ADRs Advance; Connect Biopharma Climbs 19%	Apr. 05	DJ
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	Apr. 03	DJ
Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	Nov. 09	CI
Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
CanSino Biologics Enrolls First Case in Recombinant Zoster Vaccine Trial in Canada	Nov. 09	MT
Barinthus Biotherapeutics plc(NasdaqGM:BRNS) added to NASDAQ Composite Index	Nov. 08	CI
Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index	Nov. 06	CI
ADRs End Higher; TC Biopharm PLC Climbs 19%	23-10-30	DJ
ADRs Advance, Akso Health Group Rises 29.6%	23-10-06	DJ
ADRs End Higher; Dunxin Financial Holdings Ltd. Climbs 11.7%	23-10-04	DJ
ADRs Slump; Turbo Energy S.A. Declines 37.7%	23-09-25	DJ
Health Care Up on Defensive Bets -- Health Care Roundup	23-09-25	DJ
Sector Update: Health Care Stocks Advancing Late Afternoon	23-09-25	MT
Sector Update: Health Care	23-09-25	MT
Vaccitech Shares Rise After Alliance Global Partners Begins Coverage With Buy Rating	23-09-25	MT
Top Midday Gainers	23-09-25	MT
Alliance Global Partners Initiates Coverage on Vaccitech with Buy Rating, $12 Price Target	23-09-25	MT
Morgan Stanley Downgrades Vaccitech to Equal Weight From Overweight, Cuts Price Target to $3.25 From $14	23-09-25	MT
Arbutus Biopharma Discontinues Coronavirus, Oral RNA Destabilizer Programs, Focuses on Hepatitis B Virus Treatment Assets	23-09-11	MT
Morgan Stanley Adjusts Price Target on Vaccitech to $14 From $15, Maintains Overweight Rating	23-08-18	MT
Earnings Flash (VACC) VACCITECH Posts Q2 Revenue $334,000	23-08-10	MT
Vaccitech plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart Barinthus Biotherapeutics plc

Duration

Period

More charts

Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.5 USD

Average target price

7.4 USD

Spread / Average Target

+196.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BARINTHUS BIOTHERAPEUTICS PLC	-32.25%	97.3M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Biotechnology & Medical Research

Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer

Latest news about Barinthus Biotherapeutics plc

Chart Barinthus Biotherapeutics plc

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research